Cancer Drug Resistance

Cancer Drug Resistance is a gold open access oncology journal launched in 2018 by OAE Publishing, dedicated to the mechanisms, biomarkers and therapeutic reversal of resistance to anticancer treatment, with a 2025 Journal Impact Factor of 7.6《癌症耐药》（Cancer Drug Resistance）由（OAE Publishing）于 2018 年创办，为金色开放获取肿瘤学期刊，专注抗癌治疗耐药的机制、生物标志物与逆转策略，2025 年影响因子为 7.6。

Scope

• Intrinsic, acquired and adaptive resistance are all in scope, together with the biological and pharmacological factors that determine tumour sensitivity原发耐药、获得性耐药与适应性耐药均在范围内，并涵盖决定肿瘤敏感性的生物学与药理学因素。
• Drug design and delivery, drug distribution, cellular pharmacology and influx or efflux transporters including ATP-binding cassette proteins are covered药物设计与递送、药物分布、细胞药理学以及包括三磷酸腺苷结合盒蛋白在内的流入与外排转运体均被覆盖。
• Drug targets and target modification, receptor-ligand interactions and cellular signalling pathways are treated as resistance mechanisms in their own right药物靶点与靶点修饰、受体配体相互作用及细胞信号通路本身即被视为耐药机制。
• Drug activation, phase I and phase II metabolism, degradation, sequestration, DNA damage and repair are part of the pharmacological scope药物活化、第一相与第二相代谢、降解、隔离以及 DNA 损伤与修复属于药理学范围。
• Tumour heterogeneity and evolution, epigenetic and transcriptional regulation, phenotypic plasticity and tumour microenvironment interactions are included肿瘤异质性与演化、表观遗传与转录调控、表型可塑性以及肿瘤微环境互作均被纳入。
• Biomarkers that predict resistance, methods for detecting and monitoring it, and clinical patterns of treatment failure are within scope预测耐药的生物标志物、耐药检测与监测方法以及治疗失败的临床规律均在范围内。
• Strategies that prevent, delay or overcome resistance are welcomed across chemotherapy, endocrine therapy, targeted agents, immunotherapy, antibody-drug conjugates and radioligand therapy预防、延缓或克服耐药的策略受到欢迎，涵盖化疗、内分泌治疗、靶向药、免疫治疗、抗体偶联药物与放射性配体治疗。

History

• The journal was founded in March 2018 by OAE Publishing, with Godefridus J. Peters as editor-in-chief and the inaugural issue released online on 19 March 2018该刊由（OAE Publishing）于 2018 年 3 月创办，（Godefridus J. Peters）任主编，创刊号于 2018 年 3 月 19 日在线发布。^[1]
• It joined COPE in 2019, was indexed in Scopus in 2021, and entered the Emerging Sources Citation Index and PubMed Central in 2022该刊 2019 年加入（COPE），2021 年被（Scopus）收录，2022 年进入（Emerging Sources Citation Index）与（PubMed Central）。
• A first impact factor of 3.7 was reported in June 2023, followed by 4.6 for 2023 data, 5.2 for 2024 and 7.6 for 2025该刊于 2023 年 6 月获得首个影响因子 3.7，其后 2023 年数据为 4.6，2024 年为 5.2，2025 年为 7.6。
• In January 2024 the journal moved from quarterly to continuous publication, and each article is deposited in PubMed Central on publication2024 年 1 月，该刊由季刊改为连续出版，每篇论文上线即存入（PubMed Central）。
• A Special Collection column was introduced in July 2023, grouping papers around themes such as transporter-mediated resistance and KRAS inhibitor resistance该刊 2023 年 7 月推出专题合集栏目，围绕转运体介导耐药、KRAS 抑制剂耐药等主题集结论文。
• Articles are published under a gold open access model with an article processing charge, with no subscription barrier to readers该刊采用金色开放获取模式并收取文章处理费，读者端没有订阅屏障。

Editors

• Godefridus J. Peters, professor of medical oncology at Amsterdam UMC, has led the journal since its launch and works on ABC transporters and pharmacogenetics（Godefridus J. Peters）为阿姆斯特丹大学医学中心肿瘤内科教授，自创刊起担任主编，研究三磷酸腺苷结合盒转运体与药物遗传学。
• The median time from submission to first editorial decision is nine days, a figure the publisher highlights on the journal home page投稿至首次编辑决定的中位时间为 9 天，出版方在期刊首页突出这一指标。
• The journal publishes original research, reviews, commentaries and letters, and runs special issues on focused resistance topics该刊刊载原创研究、综述、评论与读者来信，并围绕具体耐药主题组织特刊。
• An early-career editorial board was created to bring younger investigators into manuscript handling and peer review该刊设立青年编委会，让较年轻的研究者参与稿件处理与同行评议。
• Editorial operations run from the publisher's offices, with an editorial office reachable by email for scope enquiries before submission编辑事务由出版方办公室承担，作者可在投稿前通过邮件向编辑部咨询范围问题。